Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases

A disease and glycolipid technology, applied in the field of new synthetic C-glycolipids, which can solve the problems of reducing in vivo efficacy and short half-life of α-GalCer
CN1964626AInactive Publication Date: 2007-05-16NEW YORK UNIV +1
5 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NEW YORK UNIV
Publication Date
2007-05-16
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention is directed to novel compounds of formulae (I), (II) and (III): wherein X is O or NH; R<3> is OH or a monosaccharide and R<4> is hydrogen, or R<3> is hydrogen and R<4> is OH or a monosaccharide; R<5> is hydrogen or a monosaccharide; and pharmaceutically acceptable salts or esters thereof. The invention is also directed to the use of the compounds both directly and as immune adjuvants for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the intermediates which can be used to make these novel compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention was made with Government support under Lot No. R21AI47840-01A1 awarded by National Institute of Health / National Institute of Allergy and Infectious Diseases and Lot No. R01 GM60271 awarded by National Institute of Health / General Medical Sciences. Accordingly, the US Government has certain rights in this invention. field of invention

[0002] The present invention relates to a new type of synthetic C-glycolipid, which can be used in the treatment of infectious diseases, cancer and autoimmune diseases (direct administration and as an adjuvant by improving the immunogenicity of various antigens). Methods of making this novel synthetic C-glycolipid are also disclosed. Background of the invention

[0003] Glycolipids are molecules normally present in the plasma membrane of animal and plant cells. Glycolipids contain oligosaccharides bonded to lipid components. Glycosphingolipids are complex glycolipids containing ceramides as lipid components. One class o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More